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A B S T R A C T
Autosomal dominant Alzheimer's disease (ADAD) is a small subset of Alzheimer's disease that is genetically
determined with 100% penetrance. It provides a valuable window into studying the course of pathologic pro-
cesses that leads to dementia. Arterial spin labeling (ASL) MRI is a potential AD imaging marker that non-
invasively measures cerebral perfusion. In this study, we investigated the relationship of cerebral blood flow
measured by pseudo-continuous ASL (pCASL) MRI with measures of cerebral metabolism (FDG PET) and
amyloid deposition (Pittsburgh Compound B (PiB) PET). Thirty-one participants at risk for ADAD (age
39 ± 13 years, 19 females) were recruited into this study, and 21 of them received both MRI and FDG and PiB
PET scans. Considerable variability was observed in regional correlations between ASL-CBF and FDG across
subjects. Both regional hypo-perfusion and hypo-metabolism were associated with amyloid deposition. Cross-
sectional analyses of each biomarker as a function of the estimated years to expected dementia diagnosis in-
dicated an inverse relationship of both perfusion and glucose metabolism with amyloid deposition during AD
development. These findings indicate that neurovascular dysfunction is associated with amyloid pathology, and
also indicate that ASL CBF may serve as a sensitive early biomarker for AD. The direct comparison among the
three biomarkers provides complementary information for understanding the pathophysiological process of AD.
1. Introduction
Alzheimer's disease (AD), as the most common form of dementia, is
one of the leading causes of death in the United States. Converging
evidence indicates that AD pathology begins years or decades before the
clinical symptoms appear (Bateman et al., 2012; Dubois et al., 2016;
Frisoni, 2012). Longitudinal studies of AD biomarkers therefore take
many years to capture the full pathologic processes leading to de-
mentia. Fully-penetrant autosomal dominant AD (ADAD) due to PSEN1,
PSEN2, or APP mutations provides a valuable window for studying
biomarkers across the cascade of AD pathology by taking advantage of
the essentially 100% penetrance for the future development of AD with
similar age of onset within families and mutation type (Ryman et al.,
2014; Bateman et al., 2011; Schindler & Fagan, 2015). Therefore, we
can estimate at what point cognitive, behavioral, imaging, and bio-
chemical changes are occurring with respect to the onset of clinical
signs. At least some findings in this population will likely be applicable
to late-onset AD (LOAD) as ADAD and LOAD have similar, though not
identical, clinical features, amyloid plaque and neurofibrillary tangle
pathology, and early cerebrospinal fluid changes (Bateman et al.,
2012).
Over the past decade, various imaging modalities including positron
emission tomography (PET) and magnetic resonance imaging (MRI)
have been investigated as surrogate biomarkers of AD (S Zhang et al.,
2014a; Vlassenko et al., 2012; Ewers et al., 2011; Mosconi et al., 2010;
Smailagic et al., 2015; Fennema-Notestine et al., 2009; Frisoni et al.,
2010; Berti et al., 2010). Brain atrophy (Frisoni et al., 2010; McDonald
et al., 2009; Vemuri, 2010), cerebral perfusion (Binnewijzend et al.,
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2013; Binnewijzend et al., 2016), metabolism (Mosconi et al., 2010;
Mosconi, 2005), and amyloid and Tau deposition (Forsberg et al., 2008;
Small et al., 2006) have been extensively quantified. 18F-FDG PET is
used to assess the neurodegenerative processes in AD by measuring
glucose metabolism (Smailagic et al., 2015; Mosconi, 2005). Reduction
of regional cerebral metabolism has been well characterized in AD
patients, and even in MCI patients (Alexander et al., 2002; Mosconi
et al., 2009). Many studies suggest cerebral metabolic changes mea-
sured using FDG PET can occur as early as the third decade of life
(Reiman et al., 2004; Loessner et al., 1995). [11C]Pittsburgh compound
B ([11C]PiB) PET amyloid imaging (Klunk et al., 2004) has been widely
used since the accumulation of amyloid β plaques in the brain is
thought to play a causative role in AD based on the amyloid cascade
hypothesis (Hardy & Higgins, 1992). Specifically, the tracer kinetic
modeling of PiB PET yields multiple parameters, including the dis-
tribution volume ratio (DVR) of PiB, which is used for the assessment of
amyloid deposition, and R1, which is related to tracer delivery, pro-
viding information on regional perfusion (Lammertsma & Hume, 1996;
Logan, 2000).
While the presence of amyloid plaques is recognized as a central
event in the pathogenesis of AD, there is growing evidence that vascular
factors play an important role as well (Dickstein et al., 2010; Murray
et al., 2011). Decreased regional cerebral blood flow (CBF) has been
extensively studied as a possible biomarker of AD (Hays et al., 2016).
Arterial spin labeling (ASL) provides a noninvasive means of quanti-
fying regional CBF by MRI, which utilizes magnetically labeled arterial
blood water as an endogenous tracer (Detre et al., 2009). Compared to
15O-water PET perfusion imaging, ASL does not involve radiation or
contrast injection, and provides absolute CBF measurement and allows
easy registration with structural MRI. Over the past few years, several
groups have successfully applied ASL MRI to AD (Alsop et al., 2010; Z
Wang et al., 2013a; Alsop et al., 2000; Johnson et al., 2005; Dai et al.,
2009; WT et al., 2010). Characteristic patterns of cerebral hypoperfu-
sion were detected using ASL MRI, mostly in late-onset AD patients
(Alsop et al., 2010; Z Wang et al., 2013a; Alsop et al., 2000; Johnson
et al., 2005; Dai et al., 2009; WT et al., 2010). A good correlation has
been demonstrated between ASL MRI and 15O-water PET in both resting
state and activation studies (Ye et al., 2000; K Zhang et al., 2014b;
Kilroy et al., 2014). More recently, a few groups began to investigate
the relationship between cerebral perfusion by ASL MRI and metabo-
lism by FDG PET (Cha et al., 2013; Chen et al., 2011), as well as be-
tween ASL MRI and PiB PET (McDade et al., 2014; Mattsson et al.,
2014). However, we are unaware of any studies that have directly
compared CBF measured by ASL MRI with both metabolism and amy-
loid deposition measured by PET in persons at risk for ADAD. There-
fore, the aim of this study was to enhance our understanding of the
contributions of both vascular, metabolic and biochemical dysfunction
to the amyloid pathology of AD by investigating the relationship among
cerebral perfusion, glucose metabolism, and amyloid deposition in a
cohort of individuals at risk for ADAD.
2. Materials and methods
2.1. Study participants
Persons known to have PSEN1, PSEN2, or APP mutations in the
family were recruited for comprehensive clinical, imaging, and bio-
chemical assessments at UCLA. A total of 31 ADAD subjects (age
39 ± 13 years, 19 females) including 23 mutation carriers
(PSEN = 19, and APP = 4) participated in this study after providing
written informed consent. Persons with significant medical or psy-
chiatric illnesses with the potential to significantly affect their cognition
were excluded.
2.2. MRI protocol
Twenty-seven participants underwent MRI scans on a 3 T Siemens
TIM Trio scanner (Erlangen, Germany) using the standard 12-channel
head coil. Two participants were excluded from data analysis due to
abnormal CBF values of whole brain (e.g.< 20 ml/100 g/min).
Pseudo-continuous ASL (pCASL) with 3D background suppressed
GRASE sequence (Kilroy et al., 2014) was performed for resting CBF
measurement with the following imaging parameters:
FOV = 220 × 220 mm2, matrix size = 64 × 64, TE/TR = 23/
3500 ms, GRAPPA rate = 2. Twenty-six 5-mm slices were acquired to
cover the whole brain with 60 repetitions. The tagging plane was po-
sitioned 90 mm inferior to the center of the imaging slab with a labeling
duration of 1500 ms and post-labeling delay (PLD) of 1500 ms. A 3D
MPRAGE sequence was performed for T1 weighted structural MRI with
the imaging parameters: 192 slices at 1 mm slice thickness, voxel si-
ze = 1 × 1× 1 mm3, TR/TE = 1620/3 ms, TI = 950 ms, TE = 3 ms,
the scan time of 6 min.
2.3. PET protocol
2.3.1. 18F-FDG PET
Twenty-three subjects participated in an 18F-FDG PET/CT scan on a
whole body scanner. Metabolic imaging with [18F]FDG-PET was per-
formed with a 3D dynamic acquisition beginning 40 min after a bolus
injection of approximately 5 mCi of FDG and lasted for 20 min. Images
were reconstructed using back of projection with a Gaussian smoothing
of 3 mm full width half-maximum (FWHM) after correction for scatter,
decay, scanner dead time, and attenuation.
2.3.2. 11C-PiB PET
Twenty-three participants received 11C-PIB PET/CT scans. Subjects
received a bolus injection of approximately 15 mCi of [11C]PiB.
Dynamic 11C-PIB PET/CT scans were acquired in list-mode for 70 min.
Raw PiB PET data were rebinned into 6 × 30 s, 4 × 180 s, and
11 × 300 s, and were reconstructed using ordered subset expectation
maximization algorithm (6 iterations, 16 subsets) with a post-re-
construction 3D Gaussian smoothing (FWHM: 3 mm× 3 mm× 3 mm).
A retrospective image-based movement correction procedure was ap-
plied to correct for possible misalignment between CT and PET scans
and between PET image frames (Ye et al., 2014).
2.4. Image processing
For pCASL data, motion correction was performed using Statistical
Parametric Mapping (SPM) 12 for control and label images, separately.
Perfusion weighed images were obtained by pair-wise subtraction be-
tween the control and label images. Quantitative CBF maps were sub-
sequently calculated using the averaged perfusion weighted images
based on a single compartment model (Kilroy et al., 2014).
All CBF, FDG PET, and PiB PET images of each subject were co-
registered to the subject's MPRAGE images, and further warped to MNI
single-subject brain template using the Symmetric Diffeomorphic
Mapping method implemented in ANTS (Avants et al., 2008). The
normalized CBF images were smoothed with a 3 mm FWHM kernel,
creating absolute CBF (absCBF) maps. A relative CBF (rCBF) map was
also generated by dividing the CBF of each voxel by the mean CBF in
the cerebellum for each subject. Summation images were generated
from FDG PET data to assess the glucose metabolism, and then were
intensity normalized to cerebellar mean intensity, generating relative
CMRGlc (rCMRGlc) images. For PiB PET images, using the combined
transformation from template to PET space, tissue time-activity curve
was generated for cerebellar grey matter (reference region), and para-
metric images of relative perfusion (R1) and distribution volume ratio
(DVR) were constructed by simplified reference tissue model (SRTM)
(Lammertsma & Hume, 1996) and Logan graphical method (Logan,
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2000), respectively.
For each subject, normalized MPRAGE images were segmented into
grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF)
compartment using SPM 12. A grey matter mask thresholded for
probabilities above 90% from the GM segmentation was applied for
CBF, rCMRGlu, DVR and R1 images before performing regional corre-
lation analysis. To specify regional correlations, the CBF, rCMRGlu, DVR
and R1 images were compared within 9 representative of regions of
interest (ROIs) from the Anatomic Labeling (AAL) template in SPM
including the frontal, parietal, occipital, and temporal lobes, amygdala,
caudate, cingulum, hippocampus, and insula. Cross-sectional analyses
of the mean CBF, rCMRGlu, and DVR of each ROI were performed as a
function of the parental age at onset. Jacobian determinants were also
calculated from the T1 structural images of each participant, which
were used for correction of expansion or contraction of a voxel during
spatial normalization (Du et al., 2006).
2.5. Statistical analysis
Regional mean values of CBF, rCMRGlu and DVR were extracted
from each ROI in each subject, which were tested for normality using
the Shapiro-Wilk W test. According to the results of normality test, the
correlations between regional mean rCBF and rCMRGlu, absCBF and
DVR, and rCMRGlu and DVR were calculated across subjects using
Pearson or Spearman's correlation coefficients. Furthermore, the asso-
ciations of the mean DVR in grey matter, which was treated as the
global amyloid deposition, with voxel-level absCBF and rCMRGlu were
also explored using a univariate regression analysis by SPM, respec-
tively. The statistical maps were thresholded at a significance of
p < 0.001 uncorrected with a cluster level threshold of 200 voxels.
Voxel-by-voxel and cross-subject correlations were calculated between
rCBF and R1 in each ROI using Pearson's correlation and Spearman's
correlation, respectively. For ROI-wise correlation analysis, statistical
significance was defined as p < 0.05 (2 tailed) uncorrected. Family
wise correction of multiple comparisons was further performed in
voxelwise analysis.
The age of symptom onset and dementia diagnosis tends to be fairly
consistent within ADAD families and within persons with the same
mutation (Ryman et al., 2014). Accordingly, one can estimate the
number of years to clinically diagnosable dementia (“adjusted age”)
based on the age of dementia diagnosis in each subject's affected parent.
Both linear and quadratic models were considered to model each
imaging biomarker as a function of adjusted age to study the pathologic
changes in Alzheimer's disease in mutation carriers for each AD-related
ROI.
3. Results
The demographic characteristics of the research participants are
listed in Table 1. There were 22 mutation-carriers and 9 non-carriers in
total. The mutation carriers and non-carriers did not differ significantly
in their age, sex, adjusted age, cognitive status, or proportion who were
carriers of the APOE ε4 allele. Twenty-one (16 mutation-carriers) out of
the total 31 subjects underwent complete assessments with ASL MRI,
FDG PET and PiB PET scans, which were used for the analysis of inter-
modality comparisons. No significance was detected between the par-
ticipants with and without completing imaging scans in their age, ad-
justed age, cognitive status and proportion of APOE ε4 carriers, except
gender (Table S1).
3.1. Spatial patterns of cerebral blood flow, metabolism, and amyloid-β
deposition
Normalized rCBF, rCMRGlu and DVR maps of the entire brain were
averaged across subjects to compare their spatial patterns. As displayed
in Fig. 1a–c, the mean rCBF and rCMRGlu maps show highly consistent
spatial patterns with high contrast between grey and white matter,
whereas PiB DVR shows a weaker contrast between cortical grey and
white matter and a higher intensity in basal ganglia and thalamus. To
further demonstrate the spatial similarity and difference between the
CBF map and the CMRGlu and DVR maps, voxel-wise correlations be-
tween the mean rCBF and rCMRGlu and between the mean absCBF and
DVR were performed in 9 CE-associated anatomical ROIs by calculating
Pearson correlation coefficients. Scatter plots between the mean rCBF
and rCMRGlu, and between the mean absCBF and DVR in the 9 ROIs are
shown in Fig. S1. Significantly positive correlations between rCBF and
rCMRGlu were observed in all the ROIs with an overall mean correlation
coefficient of r= 0.57 ± 0.16. A reduced voxel-wise correlation
(r= 0.28 ± 0.29) was obtained between absCBF and DVR.
3.2. Regional associations of cerebral blood flow, metabolism, and amyloid-
β deposition
To study the coupling between CBF and metabolism in ADAD, re-
gional correlations between the mean rCBF and mean rCMRGlc were
calculated across the 21 subjects in the 9 AD-associated anatomical
ROIs separately. The scatter plots of rCBF vs. rCMRGlc in each ROI are
shown in Fig. 2. A global correlation of 0.08 ± 0.21 was obtained
between rCBF and rCMRGlu across subjects with considerable variability
across 9 ROIs. Specifically, positive correlations were mostly found in
cortical regions including frontal, occipital, parietal and temporal
cortex, while negative correlations were seen in subcortical regions,
including amygdala, hippocampus, and insula.
The regional associations of amyloid deposition with cerebral per-
fusion and metabolism were also studied by calculating Spearman's
correlation coefficients in the 9 ROIs across subjects, as shown in Fig. 3a
and b, respectively. Overall, inverse correlations were obtained be-
tween DVR with both absCBF (r=−0.15 ± 0.16), and rCMRGlc
(r=−0.31 ± 0.23) across subjects. The stronger regional correlation
was seen in insula (r=−0.35) and cortical regions including temporal
(r =−0.31) and frontal (r=−0.32) lobes with the lowest correlation
seen in hippocampus (r=−0.001) for the cross-subject correlation of
DVR and absCBF. The higher inverse correlation between DVR and
rCMRGlu was seen in insula (r=−0.56) and cortical regions such as
frontal (r=−0.46), occipital (r =−0.46) and parietal (r=−0.47)
lobes with the lowest correlation seen in amygdala (r=−0.03).
3.3. Effects of global amyloid deposition on cerebral blood flow and cerebral
metabolism
From the voxel-level regression analysis, we found regional CBF
decreased in Frontal Mid L, Temporal Sup L, Temporal Mid&Sup R, and
Parietal Inf L (Fig. 4) as the mean PiB DVR in grey matter increased. The
findings remained significant after controlling for age, although the size
Table 1
The characteristics of the research cohort.
Characteristics ADAD mutation
carriers (N= 23)
Non-carriers (N= 8) P value
Sex (F/M) 16/7 3/5 0.12
Age (range), yr 41 ± 13 (19–64) 32 ± 11 (22–56) 0.09
Adjusted age
(range), yr
−10 ± 8 (−28–5) −17 ± 10 (−27~− 1) 0.09
CDR > 0, no. 12 4⁎ 0.48
ApoE4 carriers,
no.
4 2 0.65
Mutation type,
no.
PS:19; APP:4
CDR: Cognitive Dementia Rating Score. CDR = 0 indicates no cognitive decline.
CDR > 0 indicates cognitive decline.
⁎ 4 non-carriers were blindly found to have CDR scores of 0.5 representing question-
able cognitive impairment unrelated to early-onset AD.
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of the clusters was reduced. Significant inverse correlation was ob-
served between the mean DVR in grey matter and the extracted CBF
from each of the clusters (Fig. 4). The voxel-level regression analysis
between rCMRGlu and global DVR suggested that regional metabolism
decreased in Frontal Sup L&Mid R & Inf R, Temporal Sup R&L, Parietal
Inf R, and Precentral L as the global amyloid deposition increased
(Fig. 5). When correcting for the age effect, we still observed similar
results. No regions with significant positive correlations between global
DVR and rCMRGlu or rCBF were detected.
3.4. Trajectories of cerebral blood flow, cerebral metabolism, and amyloid
deposition in ADAD mutation carriers in AD development
Since we focused on the trajectory of each individual biomarker, all
the data available of each single modality from all the ADAD mutation
carriers were included in the cross-sectional analysis to enlarge the
sample size. Fig. 6 shows measures of cerebral blood flow, metabolism,
and amyloid deposition as a function of adjusted age in ROIs relevant to
AD processes. The cross-sectional plots show significant decline of CBF
in cortical ROIs, including frontal, occipital, parietal and temporal lobes
with adjusted age, as shown in Fig. 6a. A trend of decrease of CBF was
also seen in precuneus. No significant change in CBF was found in
hippocampus. For metabolism, only frontal cortex and several sub-
cortical regions showed significant rCMRGlu decline. Similarly, the
hippocampus did not show significant changes in glucose metabolism
(Fig. 6b). For amyloid deposition, cortical ROIs including frontal,
occipital, parietal, and temporal lobes showed increasing amyloid de-
position as their age approaches the age of dementia diagnosis, but not
in hippocampus (Fig. 6c). Significant increase of amyloid deposition
was also found in precuneus.
3.5. Comparison of cerebral perfusion measured using ASL and PiB-PET
R1 derived from dynamic PiB PET data is related to tracer delivery,
which reflects regional brain perfusion. As shown in Fig. 1d, the mean
R1 map demonstrates a distinct contrast between grey and white matter
that is highly consistent with the spatial pattern of ASL-CBF shown in
Fig. 1a. Furthermore, a strong positive correlation between mean rCBF
and R1 was obtained across voxels in each ROI with an overall mean
correlation coefficient r= 0.57 ± 0.16, as shown in Fig. 7a. The
highest correlation was seen for caudate (r= 0.74) with the lowest
correlation seen in hippocampus (r= 0.29). Intermediate positive
correlations were also seen between regional rCBF and R1 across sub-
jects (Fig. 7b), resulting in a mean correlation coefficient of
0.20 ± 0.20 with the highest correlation in parietal cortex (r= 0.50)
and lowest correlation in insula (r=−0.002).
4. Discussion
4.1. ADAD as a model for multi-modality imaging studies in AD
The relationship among cerebral perfusion, metabolism, and
Fig. 1. The averaged rCBF, rCMRGlu, PiB DVR and R1 maps
across subjects. All the mean images were normalized to a
MNI Collin template.
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amyloid deposition in people at risk for ADAD was investigated in this
study. To our knowledge, this is the first study to compare pCASL MRI
with both PiB PET and FDG PET in an ADAD cohort. Compared to late-
onset AD, ADAD shows several advantages for investigating the asso-
ciation of cerebral perfusion with other biomarkers. In late-onset AD,
abnormal CBF may be attributed to the presence of cerebrovascular
disease rather than, or in addition to AD pathology (Dai et al., 2008),
whereas persons at-risk for ADAD are younger and generally free of
significant cerebrovascular disease and therefore provide the opportu-
nity to measure CBF changes specific to AD pathophysiology. In our
Fig. 2. Regional correlation between rCBF and rCMRGlu
across 21 subjects in 9 anatomical ROIs relevant to AD.
Spearman's correlation coefficients was calculated in cau-
date, cingulum, and parietal cortex, and Pearson's correla-
tion was applied in the other ROIs.
Fig. 3. Regional correlation between CBF vs. PiB DVR (a), and rCMRGlu vs. PiB DVR (b) across 21 subjects in 9 anatomical ROIs relevant to AD. (* indicates statistically significant
correlation p < 0.05 uncorrected).
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study, a similar spatial pattern with high contrast between grey and
white matter was observed from rCBF and rCMRGlu maps, while DVR
map exhibited a weaker contrast between grey and white matter with
higher intensity in subcortical regions. Regional variability was found
between rCBF and rCMRGlu across subject. Both absCBF and rCMRGlu
show inverse associations with regional and global amyloid deposition
across subjects, suggesting reduced regional cerebral perfusion and
metabolism are related to increased amyloid deposition.
4.2. Relationship between regional CBF and CMRGlu
Cerebral perfusion is generally thought to be closely related to
metabolism. The association between cerebral perfusion and glucose
metabolism has been investigated in normal populations, which shows
an overall good correlation between CBF measured by ASL MRI and
CMRGlu measured by FDG PET (Cha et al., 2013). It is generally be-
lieved that AD development is accompanied by a reduction of neuronal
function in specific brain regions, manifested as regional reduction in
metabolism and cerebral blood flow. Specific spatial patterns of hypo-
Fig. 4. The whole brain voxel-wise correlation of CBF maps with global PiB-PET DVR values that was calculated by the mean DVR values in grey matter. The significance level was
p < 0.001 (uncorrected) with a cluster level of 200 voxels. The red regions represent the significantly inverse correlation of CBF with global DVR. The mean absolute CBF values were
extracted from the detected significant regions, and the scatter plots between CBF from the hot regions and global DVR are shown on the right side. Adjusted p values are listed in the
scatter plots.
Fig. 5. The whole brain voxel-wise correlation of rCMRGlu maps with global PiB-PET DVR values calculated by the mean DVR values in grey matter. The significant level was p < 0.001
(uncorrected) with cluster level of 200 voxels. The red regions represent the significant regions where the rCMRGlu decreased with amyloid deposition. The mean rCMRGlu values were
extracted from the detected significant regions, and the scatter plots between the mean rCMRGlu from the hot regions and global DVR are shown on the right side. Adjusted p values are
listed in the scatter plots.
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metabolism and hypo-perfusion have been reported in AD patients
(Alexander et al., 2002; Mosconi et al., 2009; Alsop et al., 2010; Z Wang
et al., 2013a). In this study, we found a similar spatial pattern of cer-
ebral perfusion and metabolism in ADAD subjects (Fig. 1a&b). How-
ever, a considerable variability of the regional correlation was observed
between cerebral perfusion and metabolism across subjects (Fig. 2).
Especially, inverse correlations were found in subcortical regions. The
regional discrepancies between rCMRGlu and rCBF in people at risk for
ADAD could be attributed to true perfusion-metabolism mismatch as a
result of neurovascular decoupling during the development of AD,
which is characterized by cerebrovascular pathology. Uncoupling be-
tween between rCMRGlu and rCBF in subcortical regions has been ob-
served under pathological conditions, such as global ischemia of brain
(Ueki et al., 1988). In this study, the observed decoupling between
rCMRGlu and rCBF in subcortical regions may be directly involved in
early AD pathology especially for persons at risk for AD at young age.
On the other hand, the regional difference between rCMRGlu and rCBF
could be caused by specific characteristics of each imaging modality
Fig. 6. The courses of regional CBF, rCMRGlu, and PiB DVR as a function of the estimated year to dementia diagnosis (adjusted age) in ROIs using quadratic fitting model from mutation
carriers. Only the regions with significant change with adjusted age as well as amygdala and precuneus were shown in the figure. Statistical Significance was defined as p < 0.05*.
Fig. 7. The regional correlation between mean rCBF and PiB R1 was shown on a voxel-by-voxel basis (a) and across subject (b) in each AD associated ROI. (* indicates statistically
significant correlation p < 0.05 with (a) and without (b) family wise correction).
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(Cha et al., 2013).
4.3. Amyloid Deposition is associated with decrease in CBF and rCMRGlu
According to the amyloid cascade hypothesis (Hardy & Higgins,
1992), the accumulation of amyloid plaques is a central event in the
pathogenesis of AD. Reduction in cerebral perfusion and metabolism
are also early events in AD pathogenesis (Murray et al., 2011). The
alteration of cerebral perfusion associated with cerebral amyloid in
ADAD was previously studied by McDade et al. (2014), which was fo-
cused on the voxel-level correlation of CBF map with global amyloid
deposition. By contrast, the present study primarily investigated the
associations between molecular, neuronal, and vascular biomarkers of
AD from AD-relevant anatomical ROIs. A negative cross-subject corre-
lation of DVR with both CBF and rCMRGlu was observed in each ROI,
which suggests that brain regions with high amyloid deposition are
associated with regional hypo-perfusion and hypo-metabolism. We also
performed voxel-wise regression analysis, and found that hypo-perfu-
sion and hypo-metabolism in regions of frontal, parietal and temporal
cortex were significantly associated with global amyloid deposition
(Figs. 4 and 5), which is in good agreement with previous findings
(McDade et al., 2014). According to the vascular hypothesis in AD
(Zlokovic, 2011), the inverse association between amyloid deposition
and cerebral perfusion suggests the cerebral vascular dysfunction may
be highly associated with amyloid pathology. However, a causal re-
lationship between hypoperfusion and amyloid deposition cannot be
concluded based on cross-sectional analyses such as these.
4.4. Evolution of regional CBF, CMRGlu and Amyloid Deposition with
ADAD progression
Compared to late-onset AD, ADAD offers a unique advantage for
studying the pathologic processes and disease progression of AD.
Making use of the estimated years to dementia diagnosis helps define
the stages of AD pathology. In this study, the courses of cerebral per-
fusion, metabolism, and amyloid deposition as a function of this ad-
justed age were studied in the 9 ROIs. Even with the relative small
sample size, we were able to obtain similar findings as those reported in
late-onset AD. Specifically, we found that ADAD mutation carriers
presented increased amyloid deposition and decreased glucose meta-
bolism and cerebral blood flow as they approached the age of dementia
diagnosis. To confirm our findings, both linear and non-linear fitting
models were considered in the cross-sectional plots, which showed very
consistent results (Fig. 6 and Fig. S2). The significant decrease of CBF
was mainly located in cortical regions, whereas significant decrease of
glucose metabolism was shown in subcortical regions. This may also
account for the variability of regional correlations between CBF and
CMRGlu. Such decoupling of regional CBF and metabolism years before
dementia onset might provide important diagnostic and prognostic in-
formation. From the time courses of DVR, we found mutation carriers
showed a rapid increase of amyloid deposition in most ROIs except for
hippocampus before symptom onset, which is consistent with the
findings from previous studies (Benzinger et al., 2013). The similar but
inverse curves between CBF and DVR trajectories further suggest that
the change of CBF may be closely associated with amyloid deposition,
indicating that pCASL MRI may offer a sensitive biomarker for the early
detection of AD pathology.
4.5. Relationship between ASL CBF and R1 of PiB PET
In this study, pCASL MRI was used for the measurement of cerebral
perfusion. Previous studies have demonstrated that ASL shows great
promise for the diagnosis, and early detection of neurodegenerative
diseases (Binnewijzend et al., 2016; Alsop et al., 2010; Z Wang et al.,
2013a; Dai et al., 2009). Because of its easy implementation and non-
invasive nature, ASL is now part of routine clinical MRI protocols. In
our study, pseudo-continuous ASL (pCASL) with 3D background-sup-
pressed single-shot GRASE was used for ASL data collection. Compared
to previous studies, background-suppressed pCASL-GRASE offers im-
proved signal-to-noise ratio and higher reproducibility, thereby pro-
viding a more reliable imaging biomarker (Kilroy et al., 2014). We
further systematically compared pCASL with R1 at both voxel-wise and
cross-subject levels. R1 was calculated from PiB PET using SUVR model
and has been considered as a proxy of relative CBF. As expected, similar
spatial patterns and significant voxel-wise correlations between rCBF
and R1 were observed in the 9 ROIs, since both parameters reflect brain
perfusion. An intermediate positive regional correlation between rCBF
and R1 was also obtained across subjects. Our findings support that
pCASL MRI is a promising non-invasive imaging technique that has the
potential to serve as a clinical tool for the measurement of CBF in AD.
4.6. Potential confounding factors and limitations
There were some potential confounding factors involved in our
analyses. First of all, partial volume effects between grey and white
matter may contribute to the correlation among CBF, rCMRGlu and
DVR. To minimize such problem, a high grey matter threshold was
applied to CBF, R1 and DVR images and only the data from voxels that
exceeded the grey matter threshold were used for data analysis.
Furthermore, this study focused on the regional association of multiple
imaging modalities across subjects, therefore, the variation induced by
the correction of partial volume in the correlation analysis is unlikely to
significantly affect the overall findings, which has been confirmed in
previous studies. Secondly, a previous study reported there was amy-
loid deposition in cerebellum in ADAD (Mann et al., 2001). Thus, the
cerebellar grey matter used as a reference region for the amyloid
quantification may reduce the effects of amyloid deposition across
subjects. Nevertheless, significant increases of amyloid accumulation
with adjusted age were still observed in the cross-sectional plots.
Thirdly, we also considered the effect of brain atrophy on the measures
of each imaging biomarkers along the cascade of AD pathologic pro-
gression. The regional values of each biomarker were divided by Ja-
cobian determinants calculated from the T1 structural images of each
participant to account for the potential effect of structural variations.
Similar biomarker courses persisted after Jacobian determinant cor-
rection, though with reduced significance (Fig. S3&4).
Our study has several limitations. First of all, a single PLD of
1500 ms was applied in ASL acquisitions, which at the time of the study
was appropriate but may be inferior to a PLD of 1800–2000 ms as re-
commended for neurodegenerative studies in the recently published
ASL white paper (Alsop et al., 2015). Moreover, arterial transit time
may vary among subjects, especially for AD patients, causing potential
inaccuracy of CBF measurement. Multi-delay ASL (Wang et al., 2013b)
could be an alternative option for CBF measurement in AD. Secondly,
there were relatively few non-mutation carriers, so we were not able to
sensitively compare the trajectories of the three biomarkers during
ADAD pathologic processes between mutation and non-mutation car-
riers. Thirdly, this is a cross-sectional study with relatively small sample
size; the causal relationship between the three biomarkers along the
ADAD development can't be fully studied. To demonstrate the temporal
and causal relationship of cerebral perfusion with metabolism and
amyloid deposition, additional longitudinal studies with adequate
sample size will be required in the future.
5. Conclusion
The regional associations among cerebral perfusion, metabolism,
and amyloid deposition in a cohort of ADAD-related subjects were in-
vestigated. Cerebral blood flow measured by pCASL MRI shows similar
spatial pattern with metabolism measured by FDG-PET across subjects.
However, there was considerable variability across brain regions,
wherein the negative correlations may indicate neurovascular
L. Yan et al. NeuroImage: Clinical 17 (2018) 751–760
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decoupling and may be related to AD pathology. Both cerebral perfu-
sion and metabolism showed inverse correlation with regional and
global amyloid deposition. This finding suggests high amyloid deposi-
tion is associated with hypo-perfusion and/or hypo-metabolism, which
is in accordance with the vascular hypothesis of AD. This study suggests
that ASL, FDG-PET and PiB-PET may provide complementary in-
formation for understanding the pathophysiology and progression of
AD.
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